Temple University School of Medicine (Clinical Campus), Pittsburgh, Pennsylvania 15232, USA.
Curr Opin Nephrol Hypertens. 2012 Sep;21(5):486-91. doi: 10.1097/MNH.0b013e328356c551.
To achieve the target blood pressure (BP) mandated by current guidelines, a large majority of patients require simultaneous administration of multiple antihypertensive agents. The purpose of this review is to focus attention on the rational selection of effective drug combinations, and upon ways to use them efficiently to achieve therapeutic objectives. The topic is widely relevant given that more than 46 million ambulatory care visits are conducted in the United States annually for hypertension management.
Recommended drug combinations exhibit complimentary pharmacology and additive BP reduction, are well tolerated, and include components with demonstrated endpoint reduction in long-term clinical trials. Recently, the choice of diuretics has emerged as a controversial issue with some evidence favoring the long-acting agent, chlorthalidone, in preference to hydrochlorothiazide. For resistant hypertension, mineralocorticoid antagonists are increasingly used as preferred add-on agents. Practical strategies for the optimal use of combination therapy continue to evolve from the older stepped-care approach to the use of low-dose combinations, and to initiation of combination therapy in a broader range of hypertensive patients.
Thoughtful use of drug combinations is critical for achieving therapeutic objectives in hypertensive individuals and populations - more rapid BP control and more effective endpoint reduction. Practical strategies for the optimal use of combination therapy continue to evolve from the older stepped-care approach to more recent recommendations favoring the use of low-dose combinations, and initiation therapy of combination treatment, particularly in patients with Stage 2 hypertension.
为了达到当前指南规定的目标血压(BP),绝大多数患者需要同时使用多种降压药物。本文的目的是关注有效药物联合的合理选择,并探讨如何有效地使用它们来实现治疗目标。鉴于每年有超过 4600 万次美国门诊就诊用于高血压管理,该主题具有广泛的相关性。
推荐的药物联合具有互补的药理学和相加的 BP 降低作用,耐受性良好,并包括在长期临床试验中显示终点降低的成分。最近,利尿剂的选择已成为一个有争议的问题,一些证据倾向于长效药物氯噻酮,而不是氢氯噻嗪。对于难治性高血压,越来越多地使用盐皮质激素拮抗剂作为首选的附加药物。从旧的阶梯治疗方法到低剂量联合治疗,以及在更广泛的高血压患者中开始联合治疗,优化联合治疗的实用策略不断发展。
在高血压患者和人群中,明智地使用药物联合是实现治疗目标的关键——更快地控制血压和更有效地降低终点。从旧的阶梯治疗方法到最近建议使用低剂量联合治疗,以及开始联合治疗,特别是在 2 期高血压患者中,优化联合治疗的实用策略不断发展。